- Home
- MGNX vs MTA Comparison
MGNX vs MTA Comparison
Compare MGNX & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MTA
- Stock Information
- Founded
- MGNX 2000
- MTA 1983
- Country
- MGNX United States
- MTA Canada
- Employees
- MGNX N/A
- MTA N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MTA
- Sector
- MGNX Health Care
- MTA
- Exchange
- MGNX Nasdaq
- MTA Nasdaq
- Market Cap
- MGNX 257.3M
- MTA 237.9M
- IPO Year
- MGNX 2013
- MTA N/A
- Fundamental
- Price
- MGNX $3.24
- MTA $3.12
- Analyst Decision
- MGNX Buy
- MTA
- Analyst Count
- MGNX 11
- MTA 0
- Target Price
- MGNX $8.57
- MTA N/A
- AVG Volume (30 Days)
- MGNX 770.4K
- MTA 381.2K
- Earning Date
- MGNX 11-05-2024
- MTA 11-14-2024
- Dividend Yield
- MGNX N/A
- MTA N/A
- EPS Growth
- MGNX N/A
- MTA N/A
- EPS
- MGNX N/A
- MTA N/A
- Revenue
- MGNX $141,329,000.00
- MTA $5,048,000.00
- Revenue This Year
- MGNX $119.63
- MTA $44.57
- Revenue Next Year
- MGNX N/A
- MTA $126.18
- P/E Ratio
- MGNX N/A
- MTA N/A
- Revenue Growth
- MGNX 16.68
- MTA 28.55
- 52 Week Low
- MGNX $2.95
- MTA $2.32
- 52 Week High
- MGNX $21.88
- MTA $4.08
- Technical
- Relative Strength Index (RSI)
- MGNX 37.79
- MTA 43.02
- Support Level
- MGNX $3.61
- MTA $3.01
- Resistance Level
- MGNX $5.10
- MTA $3.21
- Average True Range (ATR)
- MGNX 0.35
- MTA 0.16
- MACD
- MGNX -0.10
- MTA -0.03
- Stochastic Oscillator
- MGNX 4.62
- MTA 32.78
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.